Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.
Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.
oncological
solutions
AXIM Biotech is in development of a rapid (10-minute) diagnostic test that detects active biomarkers for early detection of cancer
OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)
DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client
oncological
solutions
AXIM Biotech is in development of a rapid (10-minute) diagnostic test that detects active biomarkers for early detection of cancer
OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)
DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client
About AXIM
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease.
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
The Company’s Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM’s Digital Assay Reader SAN DIEGO, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays SAN DIEGO, CA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM...
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
Leading Diagnostic Healthcare Company Highlights Value Proposition of Expanding IP Portfolio Which Includes 13 Different Filings and Allowances SAN DIEGO--(BUSINESS WIRE)--AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...